Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

被引:122
作者
Clarke, Jennifer L. [1 ]
Chang, Susan [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Div Neurooncol, San Francisco, CA 94143 USA
关键词
HIGH-GRADE GLIOMAS; PHASE-II; RADIATION NECROSIS; MALIGNANT GLIOMAS; BEVACIZUMAB; RECURRENCE; TEMOZOLOMIDE; PET; RADIOTHERAPY; CONCOMITANT;
D O I
10.1007/s11910-009-0035-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as "pseudoresponses," can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 28 条
[1]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[2]   MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].
Brandes, Alba A. ;
Franceschi, Enrico ;
Tosoni, Alicia ;
Blatt, Valeria ;
Pession, Annalisa ;
Tallini, Giovanni ;
Bertorelle, Roberta ;
Bartolini, Stefania ;
Calbucci, Fabio ;
Andreoli, Alvaro ;
Frezza, Giampiero ;
Leonardi, Marco ;
Spagnolli, Federica ;
Ermani, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197
[3]   Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma [J].
Chamberlain, Marc C. ;
Glantz, Michael J. ;
Chalmers, Lisa ;
Van Horn, Alixis ;
Sloan, Andrew E. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (01) :81-83
[4]  
Chen W, 2005, J NUCL MED, V46, P945
[5]   Clinical applications of PET in brain tumors [J].
Chen, Wei .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (09) :1468-1481
[6]   A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [J].
Cloughesy, T. F. ;
Prados, M. D. ;
Wen, P. Y. ;
Mikkelsen, T. ;
Abrey, L. E. ;
Schiff, D. ;
Yung, W. K. ;
Maoxia, Z. ;
Dimery, I. ;
Friedman, H. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7]   Transient postictal MRI changes in patients with brain tumors may mimic disease progression [J].
Finn, Michael A. ;
Blumenthal, Deborah T. ;
Salzman, Karen L. ;
Jensen, Randy L. .
SURGICAL NEUROLOGY, 2007, 67 (03) :246-250
[8]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[9]  
Hein PA, 2004, AM J NEURORADIOL, V25, P201
[10]   Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements [J].
Hu, L. S. ;
Baxter, L. C. ;
Smith, K. A. ;
Feuerstein, B. G. ;
Karis, J. P. ;
Eschlbacher, J. M. ;
Coons, S. W. ;
Nakaji, P. ;
Yeh, R. F. ;
Debbins, J. ;
Heiserman, J. E. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2009, 30 (03) :552-558